These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 26381381)

  • 1. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.
    Singh RN; Singh NN
    Adv Neurobiol; 2018; 20():31-61. PubMed ID: 29916015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA in spinal muscular atrophy: therapeutic implications of targeting.
    Singh RN; Seo J; Singh NN
    Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.
    Singh NN; Lee BM; Singh RN
    Ann N Y Acad Sci; 2015 Apr; 1341():176-87. PubMed ID: 25727246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.
    Dominguez CE; Cunningham D; Venkataramany AS; Chandler DS
    Hum Genet; 2022 Feb; 141(2):239-256. PubMed ID: 35088120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
    Singh NK; Singh NN; Androphy EJ; Singh RN
    Mol Cell Biol; 2006 Feb; 26(4):1333-46. PubMed ID: 16449646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.
    Singh NN; Howell MD; Androphy EJ; Singh RN
    Gene Ther; 2017 Sep; 24(9):520-526. PubMed ID: 28485722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing-Correcting Therapy for SMA.
    Wan L; Dreyfuss G
    Cell; 2017 Jun; 170(1):5. PubMed ID: 28666123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy.
    Singh NN; Shishimorova M; Cao LC; Gangwani L; Singh RN
    RNA Biol; 2009; 6(3):341-50. PubMed ID: 19430205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving concepts on human SMN pre-mRNA splicing.
    Singh RN
    RNA Biol; 2007; 4(1):7-10. PubMed ID: 17592254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of Patient-Identified Plasma Biomarkers in SMNĪ”7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
    Tisdale S; Pellizzoni L
    J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.
    Seo J; Singh NN; Ottesen EW; Sivanesan S; Shishimorova M; Singh RN
    PLoS One; 2016; 11(4):e0154390. PubMed ID: 27111068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW; Yokota T
    Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.